Login to Your Account


Forget those guidelines: With hard-to-beat NSCLC, 'Revel' in small victories

By Randy Osborne
Staff Writer

Monday, June 2, 2014
CHICAGO – Efficacy plus an acceptable safety profile add up to the prime outcome from a trial, but there's much value in lesser attempts, said Gregory Masters of the Helen F. Graham Cancer Center in Newark, Del., as he found himself defending the choice of a spotlighted study at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) over the weekend.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription